IOBT -
IO Biotech, Inc. Common Stock
| Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
| 0.73 0.02 (3.02%) |
--- |
0.0 (0.01%) |
0.0 (0.01%) |
0.0 (0.31%) |
0.04 (5.34%) |
0.0 (0.0%) |
0.0 (-0.6%) |
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
Earnings & Ratios
- Basic EPS:
- -0.4
- Diluted EPS:
- -0.4
- Basic P/E:
- -1.8855
- Diluted P/E:
- -1.8855
- RSI(14) 1m:
- 50.0
- VWAP:
- 0.75
- RVol:
Events
| Period |
Kind |
Movement |
Occurred At |
Related News
IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Nov 07, 2025 14:00
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
Oct 27, 2025 12:30
Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
Oct 14, 2025 17:00
Nasdaq Jumps 150 Points; US Pending Home Sales Rise
Sep 29, 2025 14:11
TGF-β Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
Sep 23, 2025 17:00
Untreated Metastatic or Unresectable Melanoma Clinical Trial Pipeline Expands as 10+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight
Aug 26, 2025 17:00
IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025
Apr 26, 2025 19:05
IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference
Feb 23, 2025 17:07
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study
Nov 07, 2024 15:00
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
Sep 14, 2024 06:30